Evidence map›Paper›PMID 35397759›Full record

ArticleJournal of neuro-oncology2022

Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.

F Mo, S Meletti, V Belcastro, S Quadri, M Napolitano, L Bello, F Dainese, M Scarpelli, I Florindo, A Mascia and 12 more

Open access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Patient-Centered Management of Brain Tumor-Related Epilepsy.Current neurology and neuroscience reports · 2024
    Review
  6. Epilepsy in Patients with Gliomas.Neurologia medico-chirurgica · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 1 country.

F MoDivision of Neuro-Oncology, Dept. Neuroscience, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Torino, Italy. francy.mo91@gmail.com.ORCID http://orcid.org/0000-0002-8469-7567
S MelettiDivision of Neurology, Modena University Hospital, Modena, Italy.
V BelcastroDivision of Neurology, Maggiore Hospital, Lodi, Italy.
S QuadriDivision of Neurology, ASST Papa Giovanni XXIII of Bergamo, Bergamo, Italy.
M NapolitanoDivision of Neurology and Stroke Unit, Hospital A. Cardarelli, Napoli, Italy.
L BelloDivision of Neurosurgical Oncology, Department of Oncology and Hemato-Oncology, Università Degli Studi Di Milano, Milan, Italy.
F DaineseDivision of Neurology, Epilepsy Centre, Hospital of Venezia, Venice, Italy.
M ScarpelliDivision of Neurology, Department of Neuroscience, AOUI Verona, Verona, Italy.
I FlorindoDivision of Neurology, Hospital of Parma, Parma, Italy.
A MasciaIRCCS Neuromed, Pozzilli, Italy.
G PaulettoNeurology Unit, Department of Neuroscience, "S. Maria Della Misericordia" University Hospital, Udine, Italy.
F BrunoDivision of Neuro-Oncology, Dept. Neuroscience, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Torino, Italy.
A PellerinoDivision of Neuro-Oncology, Dept. Neuroscience, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Torino, Italy.
G GiovanniniDivision of Neurology, Modena University Hospital, Modena, Italy.
M PolosaDivision of Neurosurgery, ASST Lariana, Como, Italy.
M SessaDivision of Neurology, ASST Papa Giovanni XXIII of Bergamo, Bergamo, Italy.
M Conti NibaliDivision of Neurosurgical Oncology, Department of Oncology and Hemato-Oncology, Università Degli Studi Di Milano, Milan, Italy.
G Di GennaroIRCCS Neuromed, Pozzilli, Italy.
G L GigliDepartment of Medicine (DAME), University of Udine, Udine, Italy.
A PisanelloNeurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS Di Reggio Emilia, Reggio Emilia, Italy.
F CavallieriClinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
R RudàDivision of Neuro-Oncology, Dept. Neuroscience, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Torino, Italy.
University of Modena and Reggio Emilia · ITIstituto Neurologico Mediterraneo · ITOspedale Papa Giovanni XXIII · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of Milan · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITAzienda Socio Sanitaria Territoriale Lariana · ITCTO Hospital · ITOspedale Antonio Cardarelli · ITOspedale Civile di Venezia · ITOspedale Maggiore · ITOspedale San Giacomo Apostolo · ITOspedale Santa Maria della Misericordia di Udine · ITUniversity of Parma · ITUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicenter national cohort of primary brain tumor patients.

methodsWe collected from 12 Italian Centers 132 patients with primary brain tumors who were treated with LCM in monotherapy. For each patient we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints).

resultsOverall, LCM led to seizure freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice. In 14 patients, we observed seizure control despite tumor progression on magnetic resonance (MRI). Multivariate analysis showed that gross-total resection at diagnosis was significantly associated with higher seizure freedom rate at 6 months. Side effects were mainly mild (grade 1-2 according to CTCAE classification) and drop-out rate was low (1.5%). Main side effects were dizziness and somnolence.

conclusionsThis is the first study showing a good efficacy and tolerability of LCM when used in monotherapy in BTRE. Further prospective studies are needed to confirm these preliminary data, investigating also quality of life and neurocognitive functions.

Indexed as

Brain NeoplasmsDrug-Related Side Effects and Adverse ReactionsEpilepsies, PartialEpilepsyAcetamidesAnticonvulsantsHumansLacosamideQuality of LifeRetrospective StudiesSeizuresTreatment OutcomeAcetamidesAnticonvulsantsLacosamideEpilepsyLacosamidePrimary brain tumorSeizure freedomSide effects

Identifiers

PMID35397759
OpenAlexW4223501051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.